New Targets, New Data, New Guidelines: Assessing Treatment Options to Personalize Care in B-Cell Lymphomas

Release Date: January 11, 2021
Expiration Date: January 11, 2022

Activity Overview

Non-Hodgkin lymphomas (NHLs) are a diverse group of lymphoproliferative disorders that can occur at any age. The American Cancer Society projects a total of 77,240 new NHL diagnoses in 2020. These new cases, combined with new cases diagnosed in previous years, will result in an estimated 19,940 deaths. More than 680,000 people in the US are currently living with NHL. More than 60 different NHL subtypes have been identified and assigned names by the World Health Organization. This program will focus on the 3 most common B-cell lymphomas including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).

This online, on-demand virtual symposium brings together renowned experts in in B-cell lymphomas. In this educational program these experts use a case-based format to discuss the latest data regarding the management of non-Hodgkin lymphoma, share their perspectives and best practices, and provide insight into the mitigation and management of key safety issues among patients with follicular lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma.

This educational activity is an archive of the live virtual symposium held on December 4, 2020.
 

Acknowledgement of Commercial Support

This activity is supported by educational grants from Genmab US Inc; Karyopharm Therapeutics; and Janssen Scientific Affairs, LLC and Pharmacyclics LLC, an AbbVie Company.
 

Target Audience

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe tumor biomarkers across NHLs in the context of NHL pathophysiology to understand the relevance of these data in determining patient prognosis and selecting appropriate therapy for patients with DLBCL, FL, and MCL
• Integrate available treatment strategies, including chemotherapy-free treatment strategies across NHLs, to better understand the efficacy and safety of these agents in patients with DLBCL, FL, and MCL
• Evaluate approaches to mitigate, monitor, and manage adverse events associated with therapeutic regimens used in the treatment of patients DLBCL, FL, and MCL
• Assess clinical trials of novel agents and therapeutic combinations for patients with DLBCL, FL, and MCL

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Brad S. Kahl, MD
Professor of Medicine
Washington University School of Medicine
St. Louis, MO

Disclosures: Grant Research Support: Acerta Pharma, ADC Therapeutics, Celgene, Genentech; Consultant: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Roche, Pharmacyclics

Laurie H. Sehn MD, MPH
Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Clinical Professor of Medicine Division of Medical Oncology
University of British Columbia
Vancouver, British Columbia

Disclosures: Grant Research Support: Roche/Genentech; Consultant: Abbvie, Apobiologix, Amgen, AstraZeneca, Acerta, Celgene, Gilead, Janssen, Genentech, Kite, Karyopharm, Lundbeck, Merck, Morphosys, Seattle Genetics, Roche, Teva, Takeda, TG Therapeutics, Verastem

Thomas E. Witzig, MD
Professor of Medicine Mayo Clinic College of Medicine
Co-PI, University of Iowa/Mayo Clinic Lymphoma SPORE
Deputy Director of Clinical Research, Mayo Clinic Cancer Center
Rochester, MN

Disclosures: Grant Research Support: Celgene, Novartis, Genetech, Acerta; Consultant: Karyopharm, Epizyme, Amgen, BeiGene, Portolla, Tessa, Morphosys, Celgene; Other: Data monitoring safety board: Seattle Genetics, Incyte

Jason Westin, MD, MS, FACP
Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine
Director, Lymphoma Clinical Research Program
Section Chief, Aggressive Lymphoma
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: Morphosys, Novartis, BristolMyers Squibb, Kite, AstraZeneca, Genentech, Curis; Consultant: Morphosys, Novartis, BristolMyers Squibb, Kite, AstraZeneca, Genentech, Curis

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.